African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1
Pilar Álvarez Jerez,Peter A. Wild Crea,Daniel M. Ramos,Emil K. Gustavsson,Mandy Radefeldt,Mary B. Makarious,Oluwadamilola O. Ojo,Kimberley J. Billingsley,Laksh Malik,Kensuke Daida,Sarah Bromberek,Carol Hu,Zachary Schneider,Aditya L. Surapaneni,Julia Stadler,Mie Rizig,Huw R. Morris,Caroline B. Pantazis,Hampton L. Leonard,Laurel Screven,Yue A. Qi,Mike A. Nalls,Sara Bandres-Ciga,John Hardy,Henry Houlden,Celeste Eng,Esteban González Burchard,Linda Kachuri,Global Parkinson’s Genetics Program (GP2),Andrew B. Singleton,Steffen Fischer,Peter Bauer,Xylena Reed,Mina Ryten,Christian Beetz,Michael Ward,Njideka U. Okubadejo,Cornelis Blauwendraat
DOI: https://doi.org/10.1101/2024.02.20.24302827
2024-02-24
Abstract:Recently, a novel African ancestry specific Parkinson’s disease (PD) risk signal was identified at the gene encoding glucocerebrosidase ( ). This variant (rs3115534-G) is carried by ∼50% of West African PD cases and imparts a dose-dependent increase in risk for disease. The risk variant has varied frequencies across African ancestry groups, but is almost absent in European and Asian ancestry populations. is a gene of high clinical and therapeutic interest. Damaging bi-allelic protein-coding variants cause Gaucher disease and mono-allelic variants confer risk for PD and Dementia with Lewy Bodies, likely by reducing the function of glucocerebrosidase. Interestingly, the novel African ancestry specific risk variant is a non-coding variant, suggesting a different mechanism of action. Using full length RNA transcript sequencing, we identified intron 8 expression in risk variant carriers (G) but not in non-variant carriers (T). Antibodies targeting the N-terminus of glucocerebrosidase showed that this intron-retained isoform is likely not protein coding and subsequent proteomics did not identify a shorter protein isoform, suggesting the disease mechanism is RNA-based. CRISPR editing of the reported index variant (rs3115534) revealed that this is the responsible sequence alteration driving production of these intron 8 containing transcripts. Follow-up analysis of this variant showed that it is in a key intronic branchpoint sequence and therefore has important implications in splicing and disease. In addition, when measuring glucocerebrosidase activity we identified a dose-dependent reduction in risk variant carriers (G). Overall, we report the functional effect of a non-coding risk variant, which acts by interfering with the splicing of functional transcripts, resulting in reduced protein levels and reduced glucocerebrosidase activity. This understanding reveals a novel therapeutic target in an underserved and underrepresented population.
Genetic and Genomic Medicine